We remain focused on releasing excellent new products to the marketplace that will enable us to meet our five-year plans. The recently announced acquisition plan for Dallas Semiconductor will certainly add to our new product efforts during this period.

In the U.S. and Silicon Valley, we can continue to compete in analog for sure. We will continue to compete as long as immigrants can continue to come to this country. But if people chose not to be here, you could have these learning centers here move.

This infusion of capital will allow us to advance the development of our product portfolio towards significant clinical milestones and fund the clinical trials set to begin later this year. Importantly, this transaction attracted investors who appreciate the promise and value of the merged company and its balanced portfolio of product candidates. We are delighted to welcome these new institutional stockholders. As a newly public company, we look forward to continuing to build our investor base and achieve our milestones.

This will get us out of the hole,

We believe that the end-market consumption for our products continues to support our revenue and earnings outlook for the fiscal year. We are comfortable with our backlog level, particularly since approximately 90 percent of our backlog is composed of proprietary products.

I think it's a wonderful opportunity for us.